Patents by Inventor Mark D. Howell
Mark D. Howell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11876798Abstract: A virtual delivery appliance may communicate with a client device over a network to provide the client device with a virtualized session for a user. A processor may be configured to communicate with the client device over the network to perform a registration operation with a relying party. An application within the virtualized session may perform an authentication operation with the relying party to access a resource. The processor may be configured to forward an authentication challenge message to the client device in response to the application receiving the authentication challenge message from the relying party for the user to access the resource, and receive an authentication answer message in response to the authentication challenge message from the client device.Type: GrantFiled: May 18, 2020Date of Patent: January 16, 2024Assignee: Citrix Systems, Inc.Inventors: Ashwin Suresh, Jason Vega Paez, Georgy Momchilov, Jayadev Marulappa Niranjanmurthy, Mark D. Howell
-
Publication number: 20200374284Abstract: A virtual delivery appliance may communicate with a client device over a network to provide the client device with a virtualized session for a user. A processor may be configured to communicate with the client device over the network to perform a registration operation with a relying party. An application within the virtualized session may perform an authentication operation with the relying party to access a resource. The processor may be configured to forward an authentication challenge message to the client device in response to the application receiving the authentication challenge message from the relying party for the user to access the resource, and receive an authentication answer message in response to the authentication challenge message from the client device.Type: ApplicationFiled: May 18, 2020Publication date: November 26, 2020Inventors: Ashwin Suresh, Jason Vega Paez, Georgy Momchilov, Jayadev Marulappa Niranjanmurthy, Mark D. Howell
-
Publication number: 20170143889Abstract: An extracorporeal system for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The system includes an absorbent matrix capable of removing an immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) such as TNF-? muteins capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. The absorbent matrix may comprise an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF-? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.Type: ApplicationFiled: August 2, 2013Publication date: May 25, 2017Inventor: Mark D. Howell
-
Patent number: 6221352Abstract: The present invention provides vaccines and a means of vaccinating a vertebrate so as to prevent or control specific T cell mediated pathologies, including autoimmune diseases and the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Such a peptide can bind to conventional antigens completed to MHC antigen presenting cells or to superantigens. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the vertebrate in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis.Type: GrantFiled: June 6, 1995Date of Patent: April 24, 2001Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo
-
Patent number: 6207645Abstract: The present invention provides vaccines and a means of vaccinating a vertebrate so as to prevent or control specific T cell mediated pathologies, including autoimmune diseases and the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Such a peptide can bind to conventional antigens complexed to MHC antigen presenting cells or to superantigens. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the vertebrate in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis.Type: GrantFiled: July 18, 1994Date of Patent: March 27, 2001Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo
-
Patent number: 6159470Abstract: The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the mammal in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides a specific .beta.-chain variable region of the T cell receptor, designated V.beta.17, which is central to the pathogenesis of rheumatoid arthritis (RA).Type: GrantFiled: June 5, 1995Date of Patent: December 12, 2000Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo
-
Patent number: 6090387Abstract: The present invention provides vaccines and a means of vaccinating a vertebrate so as to prevent or control specific T cell mediated pathologies, including autoimmune diseases and the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Such a peptide can bind to conventional antigens completed to MHC antigen presenting cells or to superantigens. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the vertebrate in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides specific .beta.Type: GrantFiled: June 6, 1995Date of Patent: July 18, 2000Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo
-
Patent number: 6007815Abstract: The present invention provides vaccines and a means of vaccinating a host so as to prevent or control specific T cell mediated pathologies. The vaccine is composed of anti-idiotypic antibodies which are internal images of a segment of the T cell receptor (TCR) present on the surface of the pathogenic T cells. The vaccine is administered to the host in a manner that induces an immune response directed against the TCR of pathologic T cell. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. Means of determining an appropriate amino acid sequence for such a vaccine are also provided.Type: GrantFiled: October 31, 1994Date of Patent: December 28, 1999Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo
-
Patent number: 5985552Abstract: The present invention provides vaccines and a means of vaccinating a vertebrate so as to prevent or control specific T cell mediated pathologies, including autoimmune diseases and the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Such a peptide can bind to conventional antigens completed to MHC antigen presenting cells or to superantigens. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the vertebrate in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides specific .beta.Type: GrantFiled: June 6, 1995Date of Patent: November 16, 1999Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo
-
Patent number: 5861164Abstract: The present invention provides vaccines and a means vaccinating a host so as to prevent or control specific T cell medicated proliferative diseases. The vaccine is composed of a pharmaceutically acceptable medium and a segment of the T cell receptor (TCR) present on the surface of the T cells mediating the disease. The vaccine is administered to the host in a manner that induces an immune response directed against the TCR of a pathologic T cell. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. Means of determining an appropriate amino acid sequence for such a vaccine are also provided.Type: GrantFiled: November 1, 1993Date of Patent: January 19, 1999Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo
-
Patent number: 5837246Abstract: The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the mammal in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides a specific .beta.-chain variable region of the T cell receptor, designated V.beta.17, which is central to the pathogenesis of rheumatoid arthritis (RA).Type: GrantFiled: January 20, 1995Date of Patent: November 17, 1998Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo
-
Patent number: 5612035Abstract: The present invention provides vaccines and a means of vaccinating a host so as to prevent or control specific T cell mediated pathologies. The vaccine is composed of a polypeptide whose amino acid sequence corresponds to a segment of the T cell receptor (TCR) present on the surface of the pathogenic T cells. The vaccine is administered to the host in a manner that induces an immune response directed against the TCR of pathologic T cells. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. Means of determining an appropriate amino acid sequence for such a vaccine are also provided.Type: GrantFiled: August 6, 1993Date of Patent: March 18, 1997Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo